{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:53:24Z","timestamp":1793836404055,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"DOI":"10.7759\/cureus.69678","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T02:44:40Z","timestamp":1726713880000},"source":"Crossref","is-referenced-by-count":4,"title":["The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as a Type of Conservative Treatment of Endometrial Cancer in Women of Reproductive Age: A Review of the Literature and a Call for Study"],"prefix":"10.7759","author":[{"given":"Maria Zoi","family":"Bourou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkis","family":"Matsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Valsamakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Panoskaltsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2651","article-title":"Conservative treatment of endometrial cancer in women of reproductive age (review)","volume":"19","author":"Bourou MZ","year":"2023","unstructured":"Bourou MZ, Matsas A, Vrekoussis T, Mastorakos G, Valsamakis G, Panoskaltsis T. Conservative treatment of endometrial cancer in women of reproductive age (review). Mol Clin Oncol. 2023, 19:55. 10.3892\/mco.2023.2651","journal-title":"Mol Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1752548","article-title":"Autophagy in the physiological endometrium and cancer","volume":"17","author":"Devis-Jauregui L","year":"2021","unstructured":"Devis-Jauregui L, Eritja N, Davis ML, Matias-Guiu X, Llobet-Nav\u00e0s D. Autophagy in the physiological endometrium and cancer. Autophagy. 2021, 17:1077-95. 10.1080\/15548627.2020.1752548","journal-title":"Autophagy"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoac05","article-title":"ESGO\/ESHRE\/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"2023","author":"Rodolakis A","year":"2023","unstructured":"Rodolakis A, Scambia G, Planchamp F, et al.. ESGO\/ESHRE\/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023, 2023:1-20. 10.1093\/hropen\/hoac05","journal-title":"Hum Reprod Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-00508-0","article-title":"Metformin and cancer immunity","volume":"41","author":"Ma R","year":"2020","unstructured":"Ma R, Yi B, Riker AI, Xi Y. Metformin and cancer immunity. Acta Pharmacol Sin. 2020, 41:1403-9. 10.1038\/s41401-020-00508-0","journal-title":"Acta Pharmacol Sin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1041535","article-title":"The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer","volume":"13","author":"Guan J","year":"2022","unstructured":"Guan J, Chen XJ. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. Front Endocrinol (Lausanne). 2022, 13:1041535. 10.3389\/fendo.2022.1041535","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1139858","article-title":"Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis","volume":"14","author":"Shao F","year":"2023","unstructured":"Shao F, Li Y, Zhao Y. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. Front Endocrinol (Lausanne). 2023, 14:1139858. 10.3389\/fendo.2023.1139858","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051028","article-title":"Recent advances in endometrial cancer prevention, early diagnosis and treatment","volume":"16","author":"Baker-Rand H","year":"2024","unstructured":"Baker-Rand H, Kitson SJ. Recent advances in endometrial cancer prevention, early diagnosis and treatment. Cancers (Basel). 2024, 16:10.3390\/cancers16051028","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1090295","article-title":"User's guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer CF Jr","year":"2015","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015, 127:818-26. 10.1080\/00325481.2015.1090295","journal-title":"Postgrad Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/17455057241234530","article-title":"A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS","volume":"20","author":"Bader S","year":"2024","unstructured":"Bader S, Bhatti R, Mussa B, Abusanana S. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS. Womens Health (Lond). 2024, 20:17455057241234530. 10.1177\/17455057241234530","journal-title":"Womens Health (Lond)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/151695","article-title":"GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons","volume":"31","author":"Papaetis GS","year":"2022","unstructured":"Papaetis GS, Kyriacou A. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons. Adv Clin Exp Med. 2022, 31:1265-74. 10.17219\/acem\/151695","journal-title":"Adv Clin Exp Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4570-8","article-title":"Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer","volume":"18","author":"Kanda R","year":"2018","unstructured":"Kanda R, Hiraike H, Wada-Hiraike O, et al.. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer. BMC Cancer. 2018, 18:657. 10.1186\/s12885-018-4570-8","journal-title":"BMC Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4476","article-title":"Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice","volume":"35","author":"Zhang Y","year":"2016","unstructured":"Zhang Y, Xu F, Liang H, Cai M, Wen X, Li X, Weng J. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice. Oncol Rep. 2016, 35:1340-8. 10.3892\/or.2015.4476","journal-title":"Oncol Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001363","article-title":"Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway","volume":"134","author":"Zhu XX","year":"2021","unstructured":"Zhu XX, Feng ZH, Liu LZ, Zhang Y. Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway. Chin Med J (Engl). 2021, 134:576-8. 10.1097\/CM9.0000000000001363","journal-title":"Chin Med J (Engl)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24604","article-title":"GLP1R inhibits the progression of endometrial carcinoma through activation of cAMP\/PKA pathway","volume":"36","author":"Li W","year":"2022","unstructured":"Li W, Gu Y, Liu S, Ruan F, Lv W. GLP1R inhibits the progression of endometrial carcinoma through activation of cAMP\/PKA pathway. J Clin Lab Anal. 2022, 36:e24604. 10.1002\/jcla.24604","journal-title":"J Clin Lab Anal"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2023.2301324","article-title":"GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death","volume":"44","author":"Li W","year":"2024","unstructured":"Li W, Lyu W, Liu S, Ruan F, Zhang X. GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death. J Obstet Gynaecol. 2024, 44:2301324. 10.1080\/01443615.2023.2301324","journal-title":"J Obstet Gynaecol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13247","article-title":"Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression","volume":"11","author":"Shigeoka T","year":"2020","unstructured":"Shigeoka T, Nomiyama T, Kawanami T, et al.. Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression. J Diabetes Investig. 2020, 11:1137-49. 10.1111\/jdi.13247","journal-title":"J Diabetes Investig"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103242","article-title":"Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: a translational case-control study","volume":"65","author":"Mao D","year":"2021","unstructured":"Mao D, Cao H, Shi M, et al.. Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: a translational case-control study. EBioMedicine. 2021, 65:103242. 10.1016\/j.ebiom.2021.103242","journal-title":"EBioMedicine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2810259","article-title":"The effect of liraglutide on lung cancer and its potential protective effect on high-induced lung senescence and oxidative damage","volume":"28","author":"Pu Z","year":"2023","unstructured":"Pu Z, Yang Y, Qin S, Li X, Cui C, Chen W. The effect of liraglutide on lung cancer and its potential protective effect on high-induced lung senescence and oxidative damage. Front Biosci (Landmark Ed). 2023, 28:259. 10.31083\/j.fbl2810259","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00017.2014","article-title":"Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner","volume":"306","author":"Zhao H","year":"2014","unstructured":"Zhao H, Wei R, Wang L, et al.. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Am J Physiol Endocrinol Metab. 2014, 306:E1431-41. 10.1152\/ajpendo.00017.2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao X","year":"2021","unstructured":"Zhao X, Wang M, Wen Z, et al.. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021, 12:721135. 10.3389\/fendo.2021.721135","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000521","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) expression in normal and neoplastic human panceatic tissues","volume":"45","author":"Dal Molin M","year":"2016","unstructured":"Dal Molin M, Kim H, Blackford A, Sharma R, Goggins M. Glucagon-like peptide-1 receptor (GLP-1R) expression in normal and neoplastic human panceatic tissues. Pancreas. 2016, 45:613-9. 10.1097\/MPA.0000000000000521","journal-title":"Pancreas"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao C","year":"2020","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020, 68:518-25. 10.1007\/s12020-020-02223-6","journal-title":"Endocrine"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: a systematic literature review","volume":"25","author":"Feier CV","year":"2024","unstructured":"Feier CV, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: a systematic literature review. Int J Mol Sci. 2024, 25:10.3390\/ijms25084346","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00050","article-title":"Acting on hormone receptors with minimal side effect on cell proliferation: a timely challenge illustrated with GLP-1R and GPER","volume":"4","author":"Gigoux V","year":"2013","unstructured":"Gigoux V, Fourmy D. Acting on hormone receptors with minimal side effect on cell proliferation: a timely challenge illustrated with GLP-1R and GPER. Front Endocrinol (Lausanne). 2013, 4:50. 10.3389\/fendo.2013.00050","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.793530","article-title":"The GLP-1R agonist exendin-4 attenuates hyperglycemia-induced chemoresistance in human endometrial cancer cells through ROS-mediated mitochondrial pathway","volume":"11","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Cheng J, Li J, He J, Li X, Xu F. The GLP-1R agonist exendin-4 attenuates hyperglycemia-induced chemoresistance in human endometrial cancer cells through ROS-mediated mitochondrial pathway. Front Oncol. 2021, 11:793530. 10.3389\/fonc.2021.793530","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000493","article-title":"European Society of Gynecological Oncology Task Force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients","volume":"25","author":"Rodolakis A","year":"2015","unstructured":"Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, Denschlag D. European Society of Gynecological Oncology Task Force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer. 2015, 25:1258-65. 10.1097\/IGC.0000000000000493","journal-title":"Int J Gynecol Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.23.04101-5","article-title":"Exploring the potential impact of GLP-1 receptor agonists in cancer therapy","author":"Aslam B","year":"2023","unstructured":"Aslam B, Bin Zafar MD, Changez MI, et al.. Exploring the potential impact of GLP-1 receptor agonists in cancer therapy. Minerva Endocrinol (Torino). 2023, 10.23736\/S2724-6507.23.04101-5","journal-title":"Minerva Endocrinol (Torino)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2194636","article-title":"The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research","volume":"23","author":"Violette CJ","year":"2023","unstructured":"Violette CJ, Agarwal R, Mandelbaum RS, et al.. The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research. Expert Rev Anticancer Ther. 2023, 23:385-95. 10.1080\/14737140.2023.2194636","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/285643-the-potential-role-of-glucagon-like-peptide-1-glp-1-receptor-agonists-as-a-type-of-conservative-treatment-of-endometrial-cancer-in-women-of-reproductive-age-a-review-of-the-literature-and-a-call-for-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T02:44:43Z","timestamp":1726713883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/285643-the-potential-role-of-glucagon-like-peptide-1-glp-1-receptor-agonists-as-a-type-of-conservative-treatment-of-endometrial-cancer-in-women-of-reproductive-age-a-review-of-the-literature-and-a-call-for-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.69678","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}